1 of 1
Story summary
- China's Harbour BioMed secured a deal exceeding US$1.2 billion with Solstice Oncology to develop and commercialize antibody HBM4003 outside China.
- The deal includes US$50 million upfront, US$5 million cash, over US$50 million in equity, and milestones totaling US$1.1 billion.
- Jingsong Wang, Harbour BioMed CEO, said the deal goes beyond licensing and advances a biotech venture.
- The HBM4003 program aims to enhance tumor-killing effects and support biologics for immunological diseases.
